AstraZeneca (AZN) announced its long-term plan to generate $80 billion in total revenues by 2030, which is significantly higher than $43.8 million generated in 2023.By 2030, AstraZeneca plans to launch 20 new medicines, which are also expected to be key contributors to the pipeline. AstraZeneca believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. AstraZeneca will continue investing in disruptive innovation and transformative new technologi ...